| Heading: |
Pancreatic Cancer: Orphan Drugs |
| Question ID: |
1812284 |
| UIN: |
59606 |
| House: |
Commons |
| Date tabled: |
2025-06-12 |
| Asking Member ID: |
5239 |
| Asking Member display name: |
Sarah Gibson
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Sarah Gibson
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the Orphan Drug Regulations in stimulating innovation in treatments for pancreatic cancer. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-20 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Human Medicines Regulations include specific incentives to support orphan medicines, designed to encourage the development of medicines for rare diseases. The regulations enable the Medicines and Healthcare products Regulatory Agency (MHRA) to grant o... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |